
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics Inc. is recognized for its attractive current valuation, with significant upside potential suggested by a revised Net Present Value (NPV) analysis estimating a twelve-month price target increase from $9.00 to $9.25. The clinical-stage company's lead product, stenoparib, has demonstrated promising and durable benefits for patients facing advanced recurrent ovarian cancer, a group with limited treatment alternatives. Furthermore, the use of proprietary Drug Response Predictor technology aims to enhance patient selection, potentially leading to improved clinical outcomes and reinforcing the company's growth prospects.
Bears say
Allarity Therapeutics reported a net loss of $2.37 million, equating to an earnings per share (EPS) of $(0.15), which fell short of expectations of $(0.21). The company's financial outlook is negatively impacted by significant balance sheet and liquidity risks, alongside uncertainties regarding the safety and efficacy of its product candidates in clinical trials and post-market settings. Furthermore, challenges related to regulatory approvals, commercialization efforts, competition, and macroeconomic factors further contribute to concerns surrounding the company's ability to achieve sustainable profitability.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares